A Phase 2 interventional study of Scopolamine in Depression, sponsored by Massachusetts General Hospital. Terminated at 1 site in United States. Open to participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2017-05-30.
Sponsored by Massachusetts General Hospital · Phase 2, Interventional, and Treatment
The primary purpose of this study is to assess the ability of scopolamine to improve the antidepressant effects of ECT and to determine whether scopolamine will shorten the time to response and remission for patients receiving ECT.
The hypothesis are:
Electroconvulsive therapy (ECT) is a highly effective treatment for severe major depression. It has been estimated that approximately 10 percent of all patients admitted to the hospital for treatment of major depressive disorder receive ECT.
However, not all patients who receive ECT respond, and of those who do, not all achieve remission. Furthermore, while there is a wide range in the number of ECT treatments done among all people with depression, the average is approximately eight treatments. Because treatments are usually done three times per week (Monday, Wednesday, and Friday), the minimal length of stay for the average person receiving inpatient ECT is typically greater than two weeks.
Finally, ECT is not without risk, and every round of ECT incurs additional risk of not just the treatment itself, but also the risks of general anesthesia. Thus, although ECT is a robust mode of treatment for Major Depressive Disorder (MDD), there remains a need for improved treatment efficacy and speed of onset. Improving the efficacy of ECT would not only benefit individuals with MDD, but also have far-reaching effects for the health care system as it could impact the cost and resources utilized.
Ideally, an agent could be added to augment the effect of ECT, both in terms of efficacy as well as speed of onset. In 2006, Furrey et al, reported the rapid antidepressant effect of the antimuscarinic drug, scopolamine, delivered parenterally. Significant antidepressant effect was found after the first scopolamine administration. The improvement was reported immediately following the first IV administration, increased across all treatments, and was sustained into the placebo crossover period.
Scopolamine is an anticholinergic muscarinic agent, with activity in the CNS and pilot data to suggest a significant impact on rapidly improving depressive symptoms in patient with MDD, when administered IV. Thus, it serves as a reasonable choice to augment the effects of ECT in the treatment of patients with MDD.
Primary Aim 1) Assess the ability of scopolamine to augment the antidepressant effects of ECT.
Hypothesis 1a: Patients receiving ECT plus scopolamine will have significantly greater mean improvement on total HAM-D score between baseline and endpoint than those receiving ECT plus placebo.
Hypothesis 1b: Patients receiving scopolamine in addition to ECT will require fewer mean ECT treatments to obtain response/remission compared to the group receiving ECT plus placebo.
Primary Aim 2) Evaluate the hypothesis that scopolamine will shorten the time to response and remission for patients receiving ECT.
Hypothesis 2: Time to response and to remission in the Scopolamine group will be significantly shorter compared to ECT alone.
Secondary Aim: Provide evidence for the tolerability of intravenous scopolamine administered during ECT.
Hypothesis 3a: There will be no between group difference (between ECT plus scopolamine vs ECT plus placebo) in mean number of ECT sessions withheld due to cognitive impairment (as determined by attending psychiatrist).
Hypothesis 3b: There will be no between group differences (between ECT plus scopolamine vs ECT plus placebo) with regards to the mean number of moderate to severe side effects.
Hypothesis 3c: There will be no significant difference between the scopolamine plus ECT group and the placebo plus ECT group on mean levels of physiological measures of ECT including: heart rate, blood pressure, seizure length, duration of muscle paralysis, duration of asystole, and energy need to induce seizure.
Exploratory Analyses: we will assess whether the scopolamine plus ECT group will have a shorter average length of stay on the inpatient psychiatric unit compared to those receiving ECT plus placebo.
We will also assess whether the scopolamine plus ECT group will have significant differences in the cognitive measures at endpoint compared to those receiving ECT plus placebo.
8,055 studies on the registry are indexed under Depression; 1,643 are open to participants now.
This study's enrollment of 7 is below the median of 84 across 6,718 interventional studies indexed under Depression.
Browse Depression studies →Massachusetts General Hospital is the lead sponsor of 2,536 studies on the registry; 446 are open to participants now.
Of its 214 completed or terminated interventional studies of FDA-regulated products, 161 (75%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Patients receiving IV scopolamine at ECT treatment
Drug: Scopolamine
Patients receiving IV placebo at ECT treatment
Drug: Scopolamine
Those receiving active drug will receive scopolamine 4mcg/kg IV with each treatment, until completion of ECT
Change in Ham D 17 Scores
Change in Ham D 17 scores measured by the difference between baseline HAM D score and HAM D score at last ECT administration. The HAM D 17 measures severity of depression with 52 being most severe and 0 being no depression. A negative change score refers to a decrease in HAM D score, while a positive change score would refer to an increase in HAM D score.
Time frame: At the time of ECT completion (about 2 weeks)
Time to Response for Patients Receiving ECT
The number of days between baseline HAM D score and HAM D score showing response (defined as a HAM D score less than half of baseline). If patients HAM D score rose above this marker at any point in the study, they were not considered as responding.The HAM D 17 measures severity of depression with 52 being most severe and 0 being no depression. .
Time frame: Duration of ECT treatment (usually 2 weeks)
Number of ECT Treatments Received to Achieve Response/Remission
The number of ECT treatments needed to achieve response (defined as a HAM D score less than half of baseline) and remission (defined as a HAM D score of less than 8). If patients HAM D score rose above these markers at any point in the study, they were not considered as responding or remitting.The HAM D 17 measures severity of depression with 52 being most severe and 0 being no depression.
Time frame: Duration of ECTtreatment (usually 2 weeks)
Number of ECT Treatments Withheld Due to Cognitive Impairment
The number of ECT treatments withheld during the course of the study due to cognitive impairment. In these cases, the participant would still be enrolled in the study but have a reduced # of ECTs. This outcome measure does not include patients who withdrew from the study.
Time frame: Duration of ECT treatment (usually 2 weeks)
The Mean Number of Moderate to Severe Side Effects
The mean number of adverse events classified as moderate to severe.
Time frame: Duration of ECT treatment (usually 2 weeks)
The Mean Levels of Physiological Measures of ECT (Blood Pressure)
Blood pressure was taken immediately post ECT administration at each ECT visit. We averaged Blood pressure for each participant at each ECT administration. The reported mean refers to the average among all participants in each group.
Time frame: Duration of ECT treatment (usually 2 weeks)
The Mean Levels of Physiological Measures of ECT (Heart Rate)
Heart rate was taken immediately post ECT administration at each ECT visit. We averaged heart rate for each participant at each ECT administration. The reported mean refers to the average among all participants in each group.
Time frame: Duration of ECT treatment (usually 2 weeks)
The Mean Levels of Physiological Measures of ECT (Seizure Duration)
Mean duration in seconds of the seizure induced by ECT for each participant at each ECT administration they received.The reported mean refers to the average among all participants in each group.
Time frame: Duration of ECT treatment (usually 2 weeks)
The Mean Levels of Physiological Measures of ECT (Energy Needed)
Mean energy needed to induce the seizure for each participant at each ECT administration they received. The reported mean refers to the average among all participants in each group.
Time frame: Duration of ECT treatment (usually 2 weeks)
| Milestone | Scopolamine | Placebo |
|---|---|---|
| Started | 4 | 3 |
| Completed | 4 | 3 |
| Not completed | 0 | 0 |
Change in Ham D 17 scores measured by the difference between baseline HAM D score and HAM D score at last ECT administration. The HAM D 17 measures severity of depression with 52 being most severe and 0 being no depression. A negative change score refers to a decrease in HAM D score, while a positive change score would refer to an increase in HAM D score.
| units on a scale | Scopolamine | Placebo |
|---|---|---|
| Change in Ham D 17 Scores | -17.50 ± 10.47 | -14.00 ± 11.00 |
The number of days between baseline HAM D score and HAM D score showing response (defined as a HAM D score less than half of baseline). If patients HAM D score rose above this marker at any point in the study, they were not considered as responding.The HAM D 17 measures severity of depression with 52 being most severe and 0 being no depression. .
| days | Scopolamine | Placebo |
|---|---|---|
| Time to Response for Patients Receiving ECT | 8.33 ± 3.21 | 5.00 ± 1.41 |
The number of ECT treatments needed to achieve response (defined as a HAM D score less than half of baseline) and remission (defined as a HAM D score of less than 8). If patients HAM D score rose above these markers at any point in the study, they were not considered as responding or remitting.The HAM D 17 measures severity of depression with 52 being most severe and 0 being no depression.
| # of ECT administrations | Scopolamine | Placebo |
|---|---|---|
| # of ECT administrations to response | 2.33 ± 2.21 | 2.50 ± 0.71 |
| # of ECT administrations to remission | 10.00 ± 3.46 | 6.50 ± 0.71 |
The number of ECT treatments withheld during the course of the study due to cognitive impairment. In these cases, the participant would still be enrolled in the study but have a reduced # of ECTs. This outcome measure does not include patients who withdrew from the study.
| ECT Treatments withheld | Scopolamine | Placebo |
|---|---|---|
| Number of ECT Treatments Withheld Due to Cognitive Impairment | 0 ± 0 | 0 ± 0 |
The mean number of adverse events classified as moderate to severe.
| number of side effects | Scopolamine | Placebo |
|---|---|---|
| The Mean Number of Moderate to Severe Side Effects | .75 ± 1.5 | 0 ± 0 |
Blood pressure was taken immediately post ECT administration at each ECT visit. We averaged Blood pressure for each participant at each ECT administration. The reported mean refers to the average among all participants in each group.
| mmHg | Scopolamine | Placebo |
|---|---|---|
| Systolic blood pressure immediately post ECT | 170.35 ± 37.88 | 131.05 ± 27.57 |
| Diastolic Blood Pressure Immediately Post ECT | 87.41 ± 16.92 | 78.80 ± 16.61 |
Heart rate was taken immediately post ECT administration at each ECT visit. We averaged heart rate for each participant at each ECT administration. The reported mean refers to the average among all participants in each group.
| Beats per minute | Scopolamine | Placebo |
|---|---|---|
| The Mean Levels of Physiological Measures of ECT (Heart Rate) | 69.24 ± 11.45 | 86.20 ± 15.62 |
Mean duration in seconds of the seizure induced by ECT for each participant at each ECT administration they received.The reported mean refers to the average among all participants in each group.
| seconds | Scopolamine | Placebo |
|---|---|---|
| The Mean Levels of Physiological Measures of ECT (Seizure Duration) | 30.25 ± 7.77 | 31.89 ± 10.56 |
Mean energy needed to induce the seizure for each participant at each ECT administration they received. The reported mean refers to the average among all participants in each group.
| joules | Scopolamine | Placebo |
|---|---|---|
| The Mean Levels of Physiological Measures of ECT (Energy Needed) | 73.83 ± 31.12 | 67.06 ± 30.02 |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Scopolamine | — | 1/4 (25%) | 1/4 (25%) |
| Placebo | — | 0/3 (0%) | 1/3 (33.3%) |
| Event | Scopolamine | Placebo |
|---|---|---|
| Recent memory lossNervous system disorders | 1/4 | 0/3 |
| Agitation requiring restraintPsychiatric disorders | 1/4 | 0/3 |
| Event | Scopolamine | Placebo |
|---|---|---|
| Hypoxia eventRespiratory, thoracic and mediastinal disorders | 0/4 | 1/3 |
| Deja vu / confusionPsychiatric disorders | 1/4 | 0/3 |
| Age, Categorical(Participants) | Scopolamine | Placebo | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 4 | 2 | 6 |
| >=65 years | 0 | 1 | 1 |
| Age, Continuous(years) | Scopolamine | Placebo | Total |
|---|---|---|---|
| Mean | 48.25 ± 8.62 | 56.67 ± 21.78 | 51.86 ± 14.68 |
| Sex: Female, Male(Participants) | Scopolamine | Placebo | Total |
|---|---|---|---|
| Female | 3 | 1 | 4 |
| Male | 1 | 2 | 3 |
| Region of Enrollment(participants) | Scopolamine | Placebo | Total |
|---|---|---|---|
| United States | 4 | 3 | 7 |
Plan to share: No
No publications or documents are linked to this record.
This study is terminated, as verified in Apr 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Massachusetts General Hospital